Literature DB >> 15023569

Decreased 5-HT1A receptor binding in amygdala of schizophrenia.

Fumihiko Yasuno1, Tetsuya Suhara, Tetsuya Ichimiya, Akihiro Takano, Tomomichi Ando, Yoshiro Okubo.   

Abstract

BACKGROUND: On the basis of postmortem data and the pharmacological action of atypical antipsychotics, serotonin-1A receptors are of interest in the study of the pathophysiology of schizophrenia. To investigate serotonin-1A receptors in schizophrenia and their relation to symptoms, we measured the availability of serotonin-1A receptors in patients with schizophrenia using positron emission tomography with [carbonyl-(11)C]WAY-100635.
METHODS: Serotonin-1A receptor binding of 11 patients with schizophrenia (8 drug-naive and 3 drug-free) was compared with that of 22 age-matched and gender-matched healthy control subjects. Symptoms were assessed using the Positive and Negative Syndrome Scale. Serotonin-1A receptor binding in selected regions of interest was quantified by binding potential obtained by the reference tissue method.
RESULTS: The regional binding potential value was lower in the amygdala by about 19% in patients with schizophrenia than in normal controls. A significant negative correlation was observed between binding potential in the amygdala and the negative and depression/anxiety symptom scores on the five-symptom subscale of the Positive and Negative Syndrome Scale.
CONCLUSIONS: Decreased serotonin-1A receptor binding in the amygdala may underlie the affective components included in the symptoms of negative and depression/anxiety in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023569     DOI: 10.1016/j.biopsych.2003.11.016

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  16 in total

Review 1.  Dysfunctional brain networks and genetic risk for schizophrenia: specific neurotransmitter systems.

Authors:  Jussi Hirvonen; Jarmo Hietala
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

2.  Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635.

Authors:  W Gordon Frankle; Ilise Lombardo; Lawrence S Kegeles; Mark Slifstein; John H Martin; Yiyun Huang; Dah-Ren Hwang; Elisa Reich; Claudine Cangiano; Roberto Gil; Marc Laruelle; Anissa Abi-Dargham
Journal:  Psychopharmacology (Berl)       Date:  2006-09-05       Impact factor: 4.530

Review 3.  Neurobiological background of negative symptoms.

Authors:  Silvana Galderisi; Eleonora Merlotti; Armida Mucci
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-03-24       Impact factor: 5.270

4.  How have developments in molecular imaging techniques furthered schizophrenia research?

Authors:  Judy L Thompson; Nina Urban; Anissa Abi-Dargham
Journal:  Imaging Med       Date:  2009-12-01

Review 5.  Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.

Authors:  Pau Celada; Analía Bortolozzi; Francesc Artigas
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

6.  The stimulus effects of 8-OH-DPAT: evidence for a 5-HT2A receptor-mediated component.

Authors:  C J Reissig; J R Eckler; R A Rabin; K C Rice; J C Winter
Journal:  Pharmacol Biochem Behav       Date:  2007-09-19       Impact factor: 3.533

Review 7.  From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments.

Authors:  O D Howes; P Fusar-Poli; M Bloomfield; S Selvaraj; P McGuire
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

8.  Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET.

Authors:  R Lanzenberger; P Baldinger; A Hahn; J Ungersboeck; M Mitterhauser; D Winkler; Z Micskei; P Stein; G Karanikas; W Wadsak; S Kasper; R Frey
Journal:  Mol Psychiatry       Date:  2012-07-03       Impact factor: 15.992

Review 9.  The Role of G Protein-Coupled Receptors (GPCRs) and Calcium Signaling in Schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines.

Authors:  Tomasz Boczek; Joanna Mackiewicz; Marta Sobolczyk; Julia Wawrzyniak; Malwina Lisek; Bozena Ferenc; Feng Guo; Ludmila Zylinska
Journal:  Cells       Date:  2021-05-17       Impact factor: 6.600

Review 10.  Anxiety disorders and schizophrenia.

Authors:  Jacqueline E Muller; Liezl Koen; Seedat Soraya; Robin A Emsley; Daniel J Stein
Journal:  Curr Psychiatry Rep       Date:  2004-08       Impact factor: 8.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.